Department of Radiation Oncology, Tata Memorial Center, Dr. E. Borges Road, Parel, Mumbai 400012, Maharashtra, India.
Med Oncol. 2009 Dec;26(4):393-401. doi: 10.1007/s12032-008-9135-2. Epub 2008 Dec 2.
The use of Ifosfamide-based chemotherapy in primary nasopharyngeal carcinoma (NPC), in neoadjuvant settings [NACT] has not been sufficiently evaluated. We present here a retrospective analysis of 78 patients of untreated, locoregionally advanced NPC patients who received Ifosfamide-Cisplatin-based NACT at our institute from 1997 to 2004. Definitive treatment comprised radical radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) using weekly Cisplatin. Post-NACT, 92% patients had a partial response (PR) while 3% had a complete locoregional response (CR). The rates of CR increased to 87% after completion of definitive treatment. With follow up (38 months), 29% patients developed recurrent/persistent disease. The local and locoregional control rates at 5 years were 76% and 73%, respectively. The 5-year overall survival (OAS) was 80% and disease-free survival was 65%. Grade III or more neutropenia was seen in 15%. Results of Ifosfamide-Cisplatin combination as a NACT in advanced NPC have been quite encouraging and need to be exploited further.
异环磷酰胺为基础的化疗在初治局部晚期鼻咽癌（NPC）中的应用[新辅助化疗（NACT）]尚未得到充分评估。我们在此回顾性分析了 78 例在我院接受异环磷酰胺联合顺铂 NACT 的未经治疗的局部晚期 NPC 患者，该研究时间为 1997 年至 2004 年。根治性放疗（RT）或同期放化疗（CCRT）采用每周顺铂。NACT 后，92%的患者有部分缓解（PR），3%的患者有完全局部缓解（CR）。在完成根治性治疗后，CR 率增加至 87%。随访（38 个月）后，29%的患者出现复发/持续性疾病。5 年局部和区域控制率分别为 76%和 73%。5 年总生存率（OAS）为 80%，无病生存率为 65%。III 级或以上中性粒细胞减少症发生率为 15%。异环磷酰胺联合顺铂作为晚期 NPC 的 NACT 结果非常令人鼓舞，需要进一步探索。
